CRYSTALLINE FORMS B, C, and D OF CANAGLIFLOZIN

摘要

Novel crystalline Forms B, C, and D of canagliflozin, processes for their preparation, pharmaceutical compositions comprising these new Forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of sodium-glucose transport proteins are disclosed. These novel Forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.

主权项

1. A crystalline form of canagliflozin or hydrate thereof, designated as Form B, having a powder X-ray diffraction pattern comprising the following 2θ values measured using Cu Kα radiation: 6.3°±0.2°, 9.4°±0.2°, and 12.6°±0.2°.